Alessandra Bearz

15.1k total citations · 3 hit papers
176 papers, 4.4k citations indexed

About

Alessandra Bearz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Alessandra Bearz has authored 176 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Pulmonary and Respiratory Medicine, 110 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Alessandra Bearz's work include Lung Cancer Treatments and Mutations (86 papers), Lung Cancer Research Studies (50 papers) and Colorectal Cancer Treatments and Studies (32 papers). Alessandra Bearz is often cited by papers focused on Lung Cancer Treatments and Mutations (86 papers), Lung Cancer Research Studies (50 papers) and Colorectal Cancer Treatments and Studies (32 papers). Alessandra Bearz collaborates with scholars based in Italy, United States and Ukraine. Alessandra Bearz's co-authors include Massimiliano Berretta, Adolfo Favaretto, Cesare Gridelli, Umberto Tirelli, Silvia Novello, Alessandro Del Conte, Sai‐Hong Ignatius Ou, Alice T. Shaw, Francesco Grossi and Enriqueta Felip and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Alessandra Bearz

171 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2015 430 citations Sai‐Hong Ignatius Ou, Alessandra Bearz et al. profile →
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

2017 412 citations Lucio Crinò, Cesare Gridelli et al. profile →
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

2017 304 citations Michele Maio, Alessandra Bearz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandra Bearz Italy	31	3.1k	2.5k	772	459	369	176	4.4k
Charles Butts Canada	32	2.6k 0.8×	3.5k 1.4×	1.1k 1.4×	356 0.8×	439 1.2×	96	5.3k
James T. Symanowski United States	28	3.1k 1.0×	1.4k 0.6×	680 0.9×	451 1.0×	415 1.1×	172	4.8k
Rafat Ansari United States	34	2.7k 0.9×	3.9k 1.6×	1.3k 1.6×	408 0.9×	651 1.8×	109	5.3k
Heather Lin United States	40	1.6k 0.5×	2.2k 0.9×	1.3k 1.6×	1.0k 2.2×	949 2.6×	173	4.9k
P. Fournel France	26	3.4k 1.1×	2.4k 1.0×	455 0.6×	305 0.7×	427 1.2×	159	4.6k
Renato Martins United States	24	1.7k 0.6×	2.6k 1.1×	811 1.1×	445 1.0×	361 1.0×	81	4.0k
Wallace Akerley United States	36	3.1k 1.0×	2.7k 1.1×	1.1k 1.4×	489 1.1×	515 1.4×	156	5.2k
Akira Inoue Japan	37	5.5k 1.8×	5.0k 2.0×	1.8k 2.3×	930 2.0×	357 1.0×	193	7.1k
Luigi Manzione Italy	29	1.3k 0.4×	2.4k 1.0×	386 0.5×	394 0.9×	637 1.7×	88	3.4k
Petronella O. Witteveen Netherlands	29	799 0.3×	2.0k 0.8×	807 1.0×	436 0.9×	702 1.9×	95	3.8k

Countries citing papers authored by Alessandra Bearz

Since Specialization

Citations

This map shows the geographic impact of Alessandra Bearz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandra Bearz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandra Bearz more than expected).

Fields of papers citing papers by Alessandra Bearz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandra Bearz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandra Bearz. The network helps show where Alessandra Bearz may publish in the future.

Co-authorship network of co-authors of Alessandra Bearz

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandra Bearz. A scholar is included among the top collaborators of Alessandra Bearz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandra Bearz. Alessandra Bearz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Majem, Margarita, Vanesa Gregorc, Giuseppe Lo Russo, et al.. (2025). LBA1: First-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. Journal of Thoracic Oncology. 20(3). S1–S1.

Carlo, Elisa De, Elisa Bertoli, Brigida Stanzione, et al.. (2025). Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 26(2). 554–554. 2 indexed citations

Bertoli, Elisa, Elisa De Carlo, Brigida Stanzione, et al.. (2025). Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches. International Journal of Molecular Sciences. 26(2). 583–583. 5 indexed citations

Carlo, Elisa De, Elisa Bertoli, Brigida Stanzione, et al.. (2024). Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance. International Journal of Molecular Sciences. 25(23). 12972–12972.

Ou, Sai‐Hong Ignatius, Benjamin Solomon, Benjamin Besse, et al.. (2024). Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report. Journal of Thoracic Oncology. 20(4). 513–520. 6 indexed citations

Bertoli, Elisa, Elisa De Carlo, Marcella Montico, et al.. (2024). EP.12B.14 Platinum-Pemetrexed Chemotherapy and Lorlatinib Combination in Advanced ALK Positive NSCLC Progressing to Lorlatinib: A Case Series. Journal of Thoracic Oncology. 19(10). S646–S646.

Boni, Luca, et al.. (2024). MA01.03 Neoadjuvant Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC: Interim Analysis of ALNEO-GOIRC-01-2020 Phase II Trial. Journal of Thoracic Oncology. 19(10). S52–S52. 1 indexed citations

Bertoli, Elisa, Elisa De Carlo, Debora Basile, et al.. (2023). Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications. International Journal of Molecular Sciences. 24(13). 10803–10803. 12 indexed citations

Porta, Camillo, Vittorio Ferrari, Paolo Andrea Zucali, et al.. (2022). Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The “retry” study from the Italian Group of Onco-Nephrology (G.I.O.N.). 6(3). 107–114. 1 indexed citations

10.

Michelotti, A., et al.. (2022). NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. International Journal of Molecular Sciences. 23(12). 6748–6748. 19 indexed citations

11.

Michelotti, A., et al.. (2022). Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials. International Journal of Molecular Sciences. 23(13). 7222–7222. 46 indexed citations

12.

Bearz, Alessandra, Enriqueta Felip, Julien Mazières, et al.. (2022). 979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study. Annals of Oncology. 33. S998–S999. 5 indexed citations

13.

Basso, Umberto, Giuseppe Procopio, Giuseppe Fornarini, et al.. (2021). Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16). Oncology. 99(12). 747–755. 2 indexed citations

14.

Mennitto, Alessia, Elena Verzoni, Francesco Cognetti, et al.. (2021). Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. Expert Review of Clinical Pharmacology. 14(2). 261–268. 7 indexed citations

15.

Rastrelli, Giulia, Isacco Desideri, Vieri Scotti, et al.. (2019). Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. Journal of Endocrinological Investigation. 43(3). 337–345. 30 indexed citations

16.

Berretta, Massimiliano, Ferdinando Martellotta, Raffaele Di Francia, et al.. (2015). Clinical presentation and outcome of non-AIDS defining cancers, in HIV-infected patients in the ART-era: the Italian Cooperative Group on AIDS and tumors activity.. PubMed. 19(19). 3619–34. 16 indexed citations

17.

Minatel, Emilio, Marco Trovò, Jerry Polesel, et al.. (2012). Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung. Journal of Thoracic Oncology. 7(12). 1862–1866. 36 indexed citations

18.

Berretta, Massimiliano, Elisa Garlassi, Bruno Cacopardo, et al.. (2011). Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard. The Oncologist. 16(9). 1258–1269. 95 indexed citations

19.

Tiseo, Marcello, Cesare Gridelli, Stefano Cascinu, et al.. (2008). An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer. 64(2). 199–206. 20 indexed citations

20.

Gridelli, Cesare, Paolo Maione, D. Amoroso, et al.. (2007). Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an Experts Panel Meeting. Critical Reviews in Oncology/Hematology. 66(2). 155–162. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact